renalytix
"renalytix" is a figurative mark owned by Renalytix AI, filed at the EUIPO on September 15, 2026. It is under examination and covers classes 5, 10, 41, 42 and 44.
- Status
- Under examination
- Filed
- September 15, 2026
- Registered
- Not yet
- Expires
- Not recorded
- Application no.
- 019422752
- Registration no.
- Not yet
- Office
- EUIPO
- European Union Intellectual Property Office
- Mark type
- Figurative mark
- 5 classes
Who owns renalytix
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Renalytix AI
RNLXY
Representative
Mewburn Ellis LLP
Mewburn Ellis LLP
What the mark covers
The products and services renalytix is filed for, grouped by Nice class.
Diagnostic preparations for medical purposes; diagnostic preparations for medical purposes for use in assessing disease progression; diagnostic preparations for medical purposes for testing, detecting, measuring and analysing biomarkers; diagnostic preparations for testing, detecting, measuring and analysing genomic biomarkers, genetic biomarkers, protein biomarkers and metabolomic biomarkers; diagnostic preparations for use with blood, urine and human tissue samples for predicting, identifying, monitoring and determining the presence, risk, progression and stage of diabetes, kidney diseases, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; medical diagnostic blood testing reagents and assays for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing and prediction; test strips for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and for assessing kidney health
Medical diagnostic instruments and equipment; blood test collection kit comprised of blood collection bag, holder for medical sample tubes, vials, and test strips, and medical sample tubes and vials for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; urine test kits comprising collection containers, tubes, vials, pipettes, swabs and transport bags for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; human tissue test kit comprising containers, tubes, vials, pipettes, swabs and transport bags for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; parts and fittings for the aforesaid
Education and training services in the field of diagnostics, diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; education and training services in the field of biomarkers; providing seminars and workshops in the field of diagnostics, diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; providing seminars and workshops in the field of biomarkers; information and consultancy services in relation to the aforesaid
Platform-as-a-Service [PaaS] featuring software platforms for medical analysis; Platform-as-a-Service [PaaS] featuring artificial intelligence, machine-learning or algorithm-based software platforms for medical analysis; Platform-as-a-Service [PaaS] featuring artificial intelligence, machine-learning or algorithm-based software platforms for medical analysis of biomarkers; Platform-as-a-Service [PaaS] services featuring software platforms for analysing biomarkers alone or in combination with multi-modal clinical and non-clinical data, laboratory measurements, demographic information, medication information and patient medical history; Platform-as-a-Service [PaaS] featuring software platforms for analysing, displaying, and reporting medical and diagnostic test results; Platform-as-a-Service [PaaS] featuring software platforms for testing, screening, and monitoring diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; Platform-as-a-Service [PaaS] featuring software platforms for medical diagnosing and prognosticating; Platform-as-a-Service [PaaS] featuring software platforms for monitoring and predicting patient response to treatment options; Platform-as-a-Service [PaaS] featuring software platforms for predicting the presence, risk, progression and stage of diabetes, kidney diseases, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; Platform-as-a-Service [PaaS] featuring risk-based predictive algorithm software for analysing and evaluating the risk of kidney diseases, diabetes, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; Software-as-a-Service [SaaS] featuring software for medical analysis; Software-as-a-Service [SaaS] featuring artificial intelligence, machine-learning or algorithm-based software for medical analysis; Software-as-a-Service [SaaS] featuring artificial intelligence, machine-learning or algorithm-based software for medical analysis of biomarkers; Software-as-a-Service [SaaS] services featuring software for analysing biomarkers alone or in combination with multi-modal clinical and non-clinical data, laboratory measurements, demographic information, medication information and patient medical history; Software-as-a-Service [SaaS] featuring software for analysing, displaying, and reporting medical and diagnostic test results; Software-as-a-Service [SaaS] featuring software for testing, screening, and monitoring diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; Software-as-a-Service [SaaS] featuring software for medical diagnosing and prognosticating; Software-as-a-Service [SaaS] featuring software for monitoring and predicting patient response to treatment options; Software-as-a-Service [SaaS] featuring software for predicting the presence, risk, progression and stage of diabetes, kidney diseases, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; Software-as-a-Service [SaaS] featuring risk-based predictive algorithm software for analysing and evaluating the risk of kidney diseases, diabetes, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; Development of new technology for others in the field of medical devices and medical diagnostic apparatuses and instruments; research, laboratory research in the field of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; medical research services; research and development services in the field of antibodies
Medical diagnostic services; medical prognostic testing services; medical analysis services for diagnosis and prognosis of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; medical testing services; medical analysis services; medical analysis services for analysing biomarkers; medical analysis services for analysing biomarkers alone or in combination with multi-modal clinical and non-clinical data, laboratory measurements, demographic information, medication information and patient medical history; medical screening services; monitoring of patients; preparation, compilation, and issuing of medical reports; medical diagnostic testing services; medical diagnostic testing using multi-modal data, methods and data observation streams; medical diagnostic testing using multi-modal data, methods and data observation streams for evaluating patients, characterising patient conditions, and evaluating the presence, risk, progression and stage of diabetes, kidney diseases, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; medical profile and medical record analysis designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms
About renalytix
Who owns the trademark "renalytix"?
The EUIPO trademark "renalytix" (application 019422752) is owned by Renalytix AI.
What is the status of "renalytix"?
Its status at the EUIPO is: under examination.
Get this data via the API
Everything on this page comes from the Signa API. Pull renalytix and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_01a0a908-9104-775d-bc3b-7a6647196cc7
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_01a0a908-9104-775d-bc3b-7a6647196cc7",
"object": "trademark",
"mark_text": "renalytix",
"status": {
"primary": "pending",
"stage": "examining"
},
"office_code": "EM",
"application_number": "019422752",
"filing_date": "2026-09-15",
"nice_classes": [
5,
10,
41,
42,
44
],
"owners": [
{
"name": "Renalytix AI",
"entity_id": "ent_019ebbcd-e128-75cd-9acb-4e4bedf5d366"
}
]
}